Clémentine Sarkozy, Eliza Anne Hawkes, Yuqin Song, Muhit Ozcan, Franck Morschhauser, Charalambos Andreadis, Alev Akyol, Parth Rao, Antonia Di Micco, Adrien Petel, Serena K. Perna, Alex F. Herrera. "Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, plus rituximab (R) versus investigator’s choice (IC) in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) who have received ≥ 1 line of systemic therapy: GOLSEEK-4, a phase (Ph) 3, randomized study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps7102